Gufic Biosciences Limited (IN:GUFICBIO)
:GUFICBIO
Want to see IN:GUFICBIO full AI Analyst Report?
GUFICBIO Stock Chart & Stats
₹338.15
-₹9.05(-1.92%)
At close: 4:00 PM EST
₹338.15
-₹9.05(-1.92%)
Day’s Range― - ―
52-Week Range₹267.50 - ₹409.00
Previous CloseN/A
Volume28.80K
Average Volume (3M)2.36K
Market Cap
₹36.12B
Enterprise Value₹40.39B
Total Cash (Recent Filing)₹880.79M
Total Debt (Recent Filing)₹3.69B
Price to Earnings (P/E)57.9
Beta0.68
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.03%
Share Statistics
EPS (TTM)5.68
Shares Outstanding100,282,510
10 Day Avg. Volume2,111
30 Day Avg. Volume2,356
Financial Highlights & Ratios
PEG Ratio-5.32
Price to Book (P/B)4.13
Price to Sales (P/S)2.91
P/FCF Ratio-152.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Sterile Injectable & Lyophilized CapabilitiesSpecialized sterile injectable and lyophilized manufacturing creates durable barriers to entry: high technical standards, regulatory compliance and capital intensity limit competition. This supports margin resilience, premium pricing and long-term contract opportunities across hospitals and institutional buyers.
Re-accelerating Revenue GrowthA return to positive top-line momentum indicates improved commercial traction across therapeutic segments. Sustained mid-single-digit to high-single-digit growth over several quarters supports scale benefits, steadier production planning and the ability to leverage fixed-cost investments.
Reasonable Gross And Operating MarginsMaintaining mid-30s gross margins and mid-teens operating margins suggests structural competitiveness in formulations manufacturing. These margins provide room to fund R&D, regulatory compliance and selective capex, supporting sustainable profitability if revenue growth steadies.
Bears Say
Sharp, Volatile Cash Generation DeclineA severe drop in operating cash flow and negative free cash flow indicate weak earnings-to-cash conversion and likely working-capital or investment strains. This reduces financial flexibility to fund capex, pay dividends or absorb shocks over the medium term without external financing.
Moderate But Rising Leverage With Falling ReturnsAlthough leverage is currently manageable, rising debt alongside declining return on equity signals narrowing returns on invested capital. That combination constrains strategic optionality and heightens refinancing and interest-rate sensitivity over the next several quarters.
Margin Compression And Declining Net IncomeProgressive margin erosion and falling net income reduce internal funding for growth and increase reliance on external capital. Persistent compression suggests competitive pricing pressure, cost inflation or mix shifts that could impede sustainable profit recovery.
Gufic Biosciences Limited News
GUFICBIO FAQ
What was Gufic Biosciences Limited’s price range in the past 12 months?
Gufic Biosciences Limited lowest stock price was ₹267.50 and its highest was ₹409.00 in the past 12 months.
What is Gufic Biosciences Limited’s market cap?
Gufic Biosciences Limited’s market cap is ₹36.12B.
When is Gufic Biosciences Limited’s upcoming earnings report date?
Gufic Biosciences Limited’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Gufic Biosciences Limited’s earnings last quarter?
Gufic Biosciences Limited released its earnings results on May 29, 2026. The company reported ₹2.18 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.18.
Is Gufic Biosciences Limited overvalued?
According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued.
Does Gufic Biosciences Limited pay dividends?
Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here
What is Gufic Biosciences Limited’s EPS estimate?
Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gufic Biosciences Limited have?
Gufic Biosciences Limited has 100,282,510 shares outstanding.
What happened to Gufic Biosciences Limited’s price movement after its last earnings report?
Gufic Biosciences Limited reported an EPS of ₹2.18 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.904%.
Which hedge fund is a major shareholder of Gufic Biosciences Limited?
Currently, no hedge funds are holding shares in IN:GUFICBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gufic Biosciences Limited
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―